CRISPR Therapeutics has been a volatile ride for shareholders, and the latest moves raise a straightforward question for ...

CRISPR Therapeutics (CRSP) has released its third quarter 2026 results, reporting revenue of US$12.67 million and a net loss ...

For years, CRISPR Therapeutics (NASDAQ: CRSP) has been the type of stock investors might call a home run swing. The company develops medicines using gene-editing technologies to treat or cure serious ...

CRISPR Therapeutics AG (CRSP) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus ...

Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, Oct. 12.

CRISPR Therapeutics' only approved product may experience increased demand. The biotech could also see significant clinical progress with some key candidates. Although the stock might jump on positive ...

CRISPR Therapeutics plans to post clinical trial updates for multiple candidates this year. The company's stock could jump if it can impress the market. Investors should keep in mind that this biotech ...

Stock forecast & analyst price target predictions based on 13 analysts offering 12-month price targets for CRSP in the last 3 months.

Bernstein maintained its rating on CRISPR Therapeutics while raising the price target to $56, signaling confidence in the gene-editing platform developer's therapeutic pipeline. CRISPR Therapeutics, ...